Inside a B.C. company’s effort to bring inhalable heroin therapy to market in Canada

This is less a "new drug launch" than a potential re-pricing of the entire addiction-treatment stack in Canada. If inhalable diacetylmorphine scales beyond a handful of patients, the biggest loser is not a single pharma incumbent but the current OAT distribution model: clinics, pharmacies, and providers optimized around methadone/buprenorphine adherence rather than high-touch, rescue-style stabilization. The second-order effect is that a product designed for the dominant consumption route today may improve retention enough to create a larger downstream market for counseling, recovery services, and chronic-care infrastructure.

The real catalyst is regulatory, not clinical. Near term, the path is binary: provincial adoption for pilot programs versus a protracted federal review that keeps this as a niche compounded therapy. If B.C. moves toward formulary inclusion, expect rapid read-through to other provinces with high overdose burden; if Ottawa or the province stalls, the commercial opportunity remains small because compounded supply cannot scale efficiently and the addressable market is gated by prescriber comfort and controlled-substance scrutiny.

The contrarian view is that the market may be overestimating how quickly "evidence-based" translates into reimbursement. The treatment has a strong efficacy narrative for hard-to-treat patients, but payers will likely demand head-to-head data on retention, diversion risk, and total-cost-of-care versus intensified long-acting OAT and emerging depot products. A skeptical take is that the biggest benefit may be operational: a new on-ramp into care, not a mass-market therapy, which caps revenue but still supports public funding for adjacent service providers.